Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor: UNC Lineberger Comprehensive Cancer Center
Study ID: NCT06902311
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Breast Cancer
DCIS
Ductal Carcinoma in Situ
Early-stage Breast Cancer

Eligibility Criteria

Sex: FEMALE
Age: 50 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Breast Radiotherapy — RADIATION
The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).

Study Details

This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique tumor bed boost given at the same time as standard radiation therapy. The FAST-Forward trial previously showed that a 1-week course of radiotherapy had similar effects to the traditional 3-week course for early-stage breast cancer after surgery. Given these favorable results, a 5-fraction WBI regimen is appealing for many patients who wish to minimize the number of treatment visits while still reducing their risk of recurrence. Generally, tumor bed boosts further decrease the risk of recurrence, but in the setting of 5-fraction WBI, a more traditional sequential boost technique is utilized.